News and Events
New AI tool classifies brain tumors using images of tumor slides
A new artificial intelligence model has been found to be highly effective at identifying brain tumor subtypes — with 95% accuracy — simply by analyzing a standard pathology image of the tumor tissue.
Read MoreSteve Rosenberg receives Szent-Györgi Prize for Progress in Cancer Research
Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, has received the 2019 Szent-Györgi Prize for Progress in Cancer Research. The award recognizes indivuduals with a seminal discovery or a body of work that has resulted in or led toward notable contributions to cancer prevention, diagnosis or treatment, and the discovery has had a lasting impact on the cancer field with a high direct impact of saving lives.
Read MoreDrug successfully treats WHIM syndrome
Researchers have discovered which genus of human papillomavirus (HPV) is responsible for warts found in patients with WHIM syndrome, a rare autoimmune disease, and determined the drug plerixafor could successfully treat those patients.
Read MoreGene mutations in Burkitt lymphoma hint at more effective treatment
Some cases of Burkitt lymphoma have long been thought to be caused by the Epstein-Barr virus. New research is revealing potential genetic mechanisms for how the virus could contribute to the disease.
Read MoreCCR staff receive NCI-NIA and Curie-NCI awards
Congratulations to the CCR staff who have been awarded the NCI-NIA Joint Fellowship and the funding opportunity offered through the NCI-NIH and PIC3i Curie.
Read MoreNew map of protein interactions hints at the underlying mechanisms of hereditary kidney cancer
A hereditary form of kidney cancer is characterized by high levels of the metabolite fumarate but how the compound fuels cancer remains a mystery. CCR researchers have mapped the proteins that fumarate interacts with, revealing new links between metabolism and malignancy.
Read MoreNew insights into mechanisms key to maintaining KRAS-mutant cancer cell survival
CCR researchers tested nearly 500 different combinations of multi-gene targeting strategies to study the mechanisms that favor the survival of KRAS-mutant colorectal and pancreatic cancer cells over normal cells. This study reveals the previously underappreciated complexity of the signaling network of the KRAS oncogene. Although work remains to be done, the research does suggest potential target combinations for more effective therapeutic interventions.
Read MoreClinical trial studies antitumor effect of sunitinib in central nervous system sarcomas
A new clinical trial is testing a cancer drug, sunitinib, on recurrent gliosarcoma and previously treated sarcomas of the central nervous system. This drug has been studied in several other types of cancer, where it was able to inhibit factors that help tumors grow and spread. Investigators want to see if sunitinib can have the same antitumor effect on sarcomas and gliosarcoma of the brain and spinal cord.
Read MoreEric Freed elected fellow of the American Academy of Microbiology
Eric Freed, Ph.D., Director of the HIV Dynamics and Replication Program, has been elected as a 2019 fellow of the American Academy of Microbiology, an honorific leadership group with the American Society for Microbiology. Fellows are elected annually through a highly selective, peer-review process based on their records of scientific achievement and original contributions that have advanced microbiology.
Read MoreTwo new compounds target a cancer-promoting RNA transcript
MALAT1 is a noncoding RNA associated with aggressive lung cancer and poor survival for patients with various tumor types. The identification of two new molecules that disable this RNA hints at new therapeutic avenues.
Read MoreClinical trial finds combination therapy effective for some biliary cancer patients
Completion of a phase I/II clinical trial found that two of 20 patients with biliary tract cancer disease experienced a partial response to treatment with the immune checkpoint inhibitor tremelimumab combined with microwave ablation therapy. Further studies are needed to understand why just a few patients responded well to this combination treatment.
Read More